Rawbank Conducts a USD 10 Million Commercial Paper to Support the Mining Industry and Strengthen the Congolese Economy
14.1.2025 11:52:00 CET | Business Wire | Press release
Rawbank, the leading bank in the Democratic Republic of Congo, announces the launch of its second issue of commercial paper for a local mining operator in the Katanga region for the sum of USD 10 million. This transaction, arranged by Rawbank's trading room, confirms the bank's role as a key player in financial innovation in the DRC, while satisfying the strategic financing needs of companies operating in major sectors of the national economy.
Following the success of its first issuance in 2022, which marked a significant step forward for the financial market in the Democratic Republic of Congo, Rawbank has affirmed its pioneering role by introducing solutions that are ever-increasingly adapted to local conditions. A major innovation in this issuance is the inclusion of a corporate guarantee - a first in the DRC - which strengthens investor security and extends the financing options available on the money market. This transaction was approved by the Central Bank of the Congo (CBC) under Instruction 50, which regulates commercial paper.
Mustafa Rawji, Chief Executive Officer of Rawbank, declared: “This transaction strengthens our leadership position in the banking sector in the DRC and underscores our commitment to support the country's economic development. By facilitating access to financing for key businesses, we are contributing to the growth and diversification of the national economy.”
Etienne Mabunda, Commercial Director of Rawbank, stated: "This second issue of commercial paper bears witness to our ability to innovate and meet the specific needs of our institutional clients. Thanks to our trading room, which complies with international standards, we were able to structure this transaction in the best possible way, thus offering our investors better yields in a competitive market environment."
The mining industry, which accounts for more than 70% of the DRC's exports, remains a vital pillar of the Congolese economy. By giving a national operator access to competitive financing, this new issuance contributes directly to boosting economic activity in the region and strengthening investor confidence while, at the same time, stimulating local savings through attractive financial products.
About Rawbank
For 23 years, with total assets of USD 5 billion, Rawbank has supported the development of the Congolese economy. The leading bank in the DRC for 12 years, Rawbank provides the most modern products and services to over 500,000 corporate, SME, and individual clients through a network of more than 100 branches across 19 provinces, a digital offering with Illicocash, internet banking, and over 250 ATMs.
Its efforts have been recognized with the African Banker Awards for Best Regional Bank in Central Africa in 2022 and 2024, a Moody’s CAA 1 rating, and ISO/IEC 20000 and ISO/IEC 27001 certifications. Rawbank’s trusted partners include IFC, BAD, TDB, BADEA, Shelter Africa, AGF, among others.
Partners who have placed their trust in RAWBANK include: AfDB, AGF, IFC, BADEA, Shelter Africa, TDB and Afrexim. For more information, visit our website:www.rawbank.com
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250109301667/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom